The ODAC provides the FDA with independent opinions and review of safety and efficacy data from outside medical experts, though the recommendations are not binding. The FDA's evaluation of this ...

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 Mechelen, Belgium; May 14, 2025, 22:01 CET; ...

A group led by researchers at the A.C.Camargo Cancer Center has succeeded in improving CAR-T cells, making them more ...

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving ...

Future research into non-Hodgkin lymphoma treatments needs to explore long-term outcomes and a better understanding biologic ...

Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three ...

A Doncaster teenager battling cancer is set to undergo a life-saving transplant op – with her family rallying around to raise ...

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to ...

Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ETCompany ParticipantsCourtney Dugan - Vice President, Head ...

Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines ...

On May 7, 2025, Y-mAbs announced that naxitamab-gqgk (DANYELZA ®) has been recommended by the National Comprehensive Cancer Network ® ("NCCN”) Clinical Practice Guidelines in Oncology (NCCN Guidelines ...